[1]刘璐,王永生,何雅億,等.晚期非小细胞肺癌患者血清细胞因子IL-1β、IL-2R、IL-6及TNF-α水平与厄洛替尼疗效的相关性研究[J].第三军医大学学报,2012,34(20):2056-2059.
 Liu Lu,Wang Yongsheng,He Yayi,et al.Correlation of serum cytokine levels with erlotinib treatment outcome in patients with advanced non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2056-2059.
点击复制

晚期非小细胞肺癌患者血清细胞因子IL-1β、IL-2R、IL-6及TNF-α水平与厄洛替尼疗效的相关性研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第20期
页码:
2056-2059
栏目:
论著
出版日期:
2012-10-30

文章信息/Info

Title:
Correlation of serum cytokine levels with erlotinib treatment outcome in patients with advanced non-small cell lung cancer
作者:
刘璐王永生何雅億任胜祥李爱武李雪飞陈晓霞戚川周彩存
同济大学附属上海市肺科医院肿瘤科,同济大学医学院肿瘤研究所
Author(s):
Liu Lu Wang Yongsheng He Yayi Ren Shengxiang Li Aiwu Li Xuefei Chen Xiaoxia Qi Chuan Zhou Caicun
Department of Oncology, Oncology Institute of Tongji University Medical School, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai, 200433, China
关键词:
非小细胞肺癌细胞因子厄洛替尼
Keywords:
non-small cell lung cancercytokineerlotinib
分类号:
R181.32;R734.2;R979.1
文献标志码:
A
摘要:
目的      探讨晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者血清细胞因子水平与厄洛替尼疗效的相关性。      方法      收集2007年1月至2011年5月同济大学附属上海市肺科医院二线/三线接受厄洛替尼治疗的晚期NSCLC患者162例。收集厄洛替尼治疗前的血样,采用ELISA测定血清中IL-1β、IL-2R、IL-6及TNF-α的表达水平。以细胞因子的中位值为临界值,将细胞因子水平分为高水平组及低水平组。采用Kaplan-Meier生存分析法对入组病例进行生存时间分析,Cox回归多因素分析法对细胞因子水平、病例临床特征与疾病进展时间(time to progression, TTP)及总生存时间(overall survival, OS)进行相关性分析。      结果      入组病例中位年龄为58岁。其中男性109例,女性53例;吸烟者74例,不吸烟者88例;病理类型为腺癌122例,鳞癌27例,其他类型13例;ECOG PS评分0~1分的病例139例,2~3分23例。在多因素分析结果中,IL-1β、IL-2R和IL-6的表达水平与年龄、性别、ECOG PS评分、吸烟状态、病例类型及肿瘤分期无明显相关性,而TNF-α的表达水平与吸烟状态相关(P=0.045)。生存分析结果显示,IL-6低表达的患者比IL-6高表达的患者有更长的生存期(P<0.01),TNF-α低表达的患者较TNF-α高表达的患者有更长的生存期(P<0.05)。Cox回归多因素分析结果显示,IL-6与TNF-α均为独立的生存相关因子(P<0.01)。      结论      在二线/三线接受厄洛替尼治疗的晚期NSCLC患者中,IL-6、TNF-α低表达的患者生存期较高表达者长,提示IL-6和TNF-α可能成为厄洛替尼在治疗晚期NSCLC中疗效的预测因子。
Abstract:
Objective      To investigate the correlation of serum levels of cytokines with clinical outcomes of erlotinib in the second- or third-line therapies to treat the patients with advanced non-small cell lung cancer (NSCLC).       Methods      One hundred and sixty-two patients with advanced NSCLC who received erlotinib as either second- or third-line treatment in our department from January 2007 to May 2011 were enrolled in this study. Their median age was 58 years. In this group, 109 were male, and 53 were female. Seventy-four were former or current smokers, and 88 were non-smokers. One hundred and twenty-two patients presented with adenocarcinoma, 27 had squamous cell carcinoma, and 13 had tumors with other types of histology. Blood samples were collected before the initiation of erlotinib, and the serum levels of IL-1β, IL-2R, IL-6 and TNF-α were assessed by enzyme-linked immunosorbent assay (ELISA). Cutoff points were defined as the median levels to divided the patients into low and high level groups (IL-1β, 26.5 pg/ml; IL-2R, 115 pmol/L; IL-6, 49.5 pg/ml; TNF-α, 48.5 pg/ml). Kaplan-Meier analysis was performed to estimate the survival time, and Cox regression analyses were employed to correlate cytokines and baseline clinical characteristics with clinical outcomes, including time to progression (TTP) and overall survival (OS).       Results      One hundred and thirty-nine patients had an eastern cooperative oncology group (ECOG) performance status of 0 to 1, while the left 23 scored at 2 to 3. Serum levels of IL-1β, IL-2R and IL-6 were not significantly associated with age, gender, ECOG performance status, smoking status, histology, or stage of tumor. But that of TNF-α was associated with smoking status (P=0.045). Survival analysis showed that patients with low levels of IL-6 had a statistically longer TTP and OS than patients with high expression (P<0.01), whereas the subgroup of patients with low levels of TNF-α also demonstrated statistically better TTP and OS than the high level group (P<0.01). Cox regression multivariate analysis indicated that these 2 cytokines were both independent factors related to survival (P<0.01).       Conclusion      For advanced NSCLC patients with erlotinib as second- or third-line treatments, those have low levels of IL-6 or TNF-α show a longer TTP and OS than those with high levels, indicating that these 2 cytokines might be served as predictive biomarkers for the efficacy of erlotinib.

参考文献/References:

刘璐, 王永生, 何雅億, 等. 晚期非小细胞肺癌患者血清细胞因子IL-1β、IL-2R、IL-6及TNF-α水平与厄洛替尼疗效的相关性研究[J]. 第三军医大学学报,2012,34(20):2056-2059.

相似文献/References:

[1]赵然尊,龙仙萍,刘志江,等.转染hRAMP1的间充质干细胞对心肌梗死后局部血管再生的作用[J].第三军医大学学报,2012,34(15):1496.
 Zhao Ranzun,Long Xianping,Liu Zhijiang,et al.MSCs with hRAMP1 overexpression improve revascularization in a rabbit model of myocardial infarction[J].J Third Mil Med Univ,2012,34(20):1496.
[2]蒋娟,易亭伍,张瑜,等.非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J].第三军医大学学报,2012,34(20):2039.
 Jiang Juan,Yi Tingwu,Zhang Yu,et al.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2039.
[3]杨庆羚,刘翩,王斌,等.EGFR-TKIs治疗晚期非小细胞肺癌并发间质性肺炎4例报告并文献复习[J].第三军医大学学报,2012,34(20):2060.
 Yang Qingling,Liu Pian,Wang Bin,et al.Interstitial pneumonia in EGFR-TKIs-treated non-small-cell lung cancer: report of 4 cases and review of the literature[J].J Third Mil Med Univ,2012,34(20):2060.
[4]斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].第三军医大学学报,2012,34(20):2063.
 Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2063.
[5]杨东,张瑛,郑新川,等.白鲜皮生物碱抗内毒素活性的研究[J].第三军医大学学报,2012,34(20):2097.
 Yang Dong,Zhang Ying,Zheng Xinchuan,et al.Anti-lipopolysaccharide activity of alkaloid components from Densefruit pittany root-bark[J].J Third Mil Med Univ,2012,34(20):2097.
[6]罗虎,罗丹,宫亮,等.联合CIK细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta分析[J].第三军医大学学报,2012,34(20):2119.
[7]卢先锋,戴楠,杨宇馨,等.血清uPAR的水平与小细胞肺癌化疗疗效及预后的关系[J].第三军医大学学报,2012,34(22):2318.
 Lu Xianfeng,Dai Nan,Yang Yuxin,et al.Serum uPAR and its relationship with chemosensitivity and prognosis in patients with small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2318.
[8]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[9]闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913.
 YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Third Mil Med Univ,2007,29(20):1913.
[10]闵发胜,陈正堂.人非小细胞肺癌与外周血淋巴细胞表达LRP的相关性研究[J].第三军医大学学报,2007,29(17):1699.
 MIN Fa-sheng,CHEN Zheng-tang.Correlation between expression of lung resistance-related protein in non-small cell lung cancer and that in peripheral blood lymphocytes[J].J Third Mil Med Univ,2007,29(20):1699.

更新日期/Last Update: 2012-10-18